Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Income from Non-Controlling Interests (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Income from Non-Controlling Interests data on record, last reported at $41000.0 in Q4 2025.

  • For Q4 2025, Income from Non-Controlling Interests rose 78.26% year-over-year to $41000.0; the TTM value through Dec 2025 reached $166000.0, up 514.81%, while the annual FY2025 figure was $166000.0, 514.81% up from the prior year.
  • Income from Non-Controlling Interests reached $41000.0 in Q4 2025 per LCTX's latest filing, up from $29000.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $100000.0 in Q2 2025 and bottomed at -$48000.0 in Q3 2023.
  • Average Income from Non-Controlling Interests over 5 years is $5823.5, with a median of -$6000.0 recorded in 2022.
  • Peak YoY movement for Income from Non-Controlling Interests: plummeted 433.33% in 2023, then skyrocketed 869.23% in 2025.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at -$8000.0 in 2021, then changed by 0.0% to -$8000.0 in 2022, then skyrocketed by 862.5% to $61000.0 in 2023, then crashed by 62.3% to $23000.0 in 2024, then skyrocketed by 78.26% to $41000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Non-Controlling Interests were $41000.0 in Q4 2025, $29000.0 in Q3 2025, and $100000.0 in Q2 2025.